PUBLIC COMPANY
saveKYOWA KIRIN
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- AbCellera becomes latest biotech to abandon dream of developing OX40 drugAbCellera has become the latest drug developer to abandon its attempts to crack the OX40 code.fiercebiotech · 7d ago
- Kura spins diabetes work into a Lilly-backed biotech startupCaspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.biopharma_dive · 2mo ago
- Mid-cap biotechs join Trump’s latest round of drug pricing dealsFocused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.biopharma_dive · 2mo ago
- STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and moreNovartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug. Read the latest pharma headlines in today's…stat · 2mo ago
- 9 midsize drugmakers climb aboard Trump’s MFN trainAstellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program…biospace · 2mo ago
- STAT+: Trump strikes nine more deals with drugmakers to lower pricesPresident Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.stat · 2mo ago
- Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategyTScan has told Fierce that its pipeline strategy remains unchanged despite Amgen walking away from a Crohn’s disease collaboration that had the potential for a windfall of half a billion dollars.fiercebiotech · 2mo ago
- Amgen sheds around 40 staffers amid continuing strugglesAmgen has laid off around 40 employees as part of “organizational changes” meant to better align operations with the company’s strategic objectives, Fierce has learned.fiercebiotech · 3mo ago
- Sanofi halts development of troubled immune drug in eczemaThe decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boos…biopharma_dive · 3mo ago
- Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot programThe planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.biopharma_dive · 4mo ago
comments(0)
5-min edit window · permanent after that